Infigratinib is provided as a single dose of minitablets for oral administration clinical trials

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

This study is testing a new medicine, infigratinib, for children under 3 years old with achondroplasia. It aims to find the right dose and see if it's safe and helps with growth. Some children will get the medicine, others a dummy pill.